<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409654</url>
  </required_header>
  <id_info>
    <org_study_id>HK-OPD-AF</org_study_id>
    <nct_id>NCT02409654</nct_id>
  </id_info>
  <brief_title>Hong Kong Outpatient AF Screening Using Single-lead ECG Device</brief_title>
  <official_title>Randomized Controlled Trial of Tailored Stroke Prevention Strategy for Newly Diagnosed Atrial Fibrillation From a Targeted Screening Program Using Handheld Single-lead ECG Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is a leading cause of mortality, morbidity and rising healthcare cost worldwide. In
      'real-world' practice, AF is often diagnosed too late at time of stroke and detection can be
      difficult because AF may be present without symptoms and intermittent in nature. Furthermore,
      utilization of adequate oral anticoagulation therapy (OAC) for stroke prevention is
      suboptimal in Hong Kong. The challenge is to identify AF prior to occurrence of stroke. The
      latest European guidelines recommend opportunistic screening for people &gt;=65 years by pulse
      palpation followed by 12-lead ECG. However, 12-lead ECG requires a trained technician, time
      consuming, requires the patient to lie on an examination couch and is not readily available
      in most outpatient clinics in Hong Kong. A practical screening test is needed. Our study aims
      to evaluate the feasibility, acceptability and incremental cost of an outpatient based
      AFscreening program using the AliveCor device. Newly diagnosed AF patients will be randomized
      to routine care versus individualized stroke prevention strategy which consists of patient
      education, stroke and bleeding risk assessment, evidence-based OAC recommendation, patient
      audit and follow-up to improve OAC utilization for stroke prevention. We envisage this study
      will provide timely evidence to inform policy decisions concerning population-based
      AF-screening for AF for stroke prevention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design

      The study consists of 2 stages. The screening study examines the feasibility of screening to
      identify undiagnosed AF in the elderly (&gt;=65 years) using a validated hand-held ECG device
      and the impact of screening on clinical and economic outcomes at the population level.
      Subsequent intervention study is a randomized-controlled study comparing an individualized
      stroke prevention strategy with routine care to prevent stroke in screen-detected AF
      patients.

      Stage 1: AF Screening Study

      Screening will be performed in 2 Cardiology and 4 Family Medicine Specialty Out-Patient
      Clinics (SOPC) at a tertiary referral hospital in Hong Kong. Subjects who meet inclusion and
      exclusion criteria will sign informed consent for Stage 1 and 2 studies separately, prior to
      conducting ECG screening.

      Stage 2: Randomized Study of Individualized Stroke Prevention vs. Routine Care

      Intervention

      Screen detected AF patients (new or known AF) from Stage 1 who are not already receiving
      appropriate OAC for stroke prevention who signed informed consent are randomized 1:1 to
      routine care or an individualized stroke prevention strategy. Participants will be randomized
      using block randomization method to assure both groups have the same number of subjects.

      Individualized Stroke Prevention Strategy

      (i) Patient education on AF and stroke risk. (ii) Assess individual risk of stroke using the
      CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii)
      Recommendation of evidence-based stroke prevention therapy (iv) Patient audit and follow-up:
      Patients not on appropriate OAC without adequate explanation will be referred to Cardiology
      SOPC for second opinion.

      Routine Care

      The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left
      to the discretion of the attending doctor.

      Follow-up

      Participants will be followed prospectively every 12 months up to 3 years for clinical events
      including death, ischemic stroke, any thromboembolic events, intracranial and other major
      bleeding and stroke prevention therapy. Screen-detected AF patients from Stage 1 who declined
      to participate in the intervention study will be followed up in a registry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Utilization rates of evidence-based stroke prevention therapy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of newly diagnosed atrial fibrillation in elderly &gt;65 years of age</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes including death, stroke and bleeding</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient awareness questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental cost per new AF case detected</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Individualized stroke prevention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient education</intervention_name>
    <description>(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion</description>
    <arm_group_label>Individualized stroke prevention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine care</intervention_name>
    <description>The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.</description>
    <arm_group_label>Individualized stroke prevention</arm_group_label>
    <arm_group_label>Routine Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 65 years or over

        Exclusion Criteria:

          -  Severe coexisting medical condition that would prevent participation (eg, dementia,
             terminal illness)

          -  Inability to read/understand the consent form and participation information statement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan P Yan, MBBS, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan P Yan, MBBS, FACC</last_name>
    <phone>(852)26323878</phone>
    <email>bryan.yan@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lally Chan</last_name>
      <phone>(852) 2632 3841</phone>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.</citation>
    <PMID>22922413</PMID>
  </reference>
  <reference>
    <citation>Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, Davies M, Lip GY. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ. 2007 Aug 25;335(7616):380. Epub 2007 Jun 29.</citation>
    <PMID>17604299</PMID>
  </reference>
  <reference>
    <citation>Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005 Oct;9(40):iii-iv, ix-x, 1-74.</citation>
    <PMID>16202350</PMID>
  </reference>
  <reference>
    <citation>Sudlow M, Rodgers H, Kenny RA, Thomson R. Identification of patients with atrial fibrillation in general practice. BMJ. 1999 Jan 23;318(7178):264.</citation>
    <PMID>9915750</PMID>
  </reference>
  <reference>
    <citation>Bj√∂rck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013 Nov;44(11):3103-8. doi: 10.1161/STROKEAHA.113.002329. Epub 2013 Aug 27.</citation>
    <PMID>23982711</PMID>
  </reference>
  <reference>
    <citation>Lee VW, Tam CS, Yan BP, Man Yu C, Yin Lam Y. Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong. Clin Cardiol. 2013 Mar;36(3):166-71. doi: 10.1002/clc.22077. Epub 2012 Nov 14.</citation>
    <PMID>23151816</PMID>
  </reference>
  <reference>
    <citation>Koponen L, Rekola L, Ruotsalainen T, Lehto M, Leino-Kilpi H, Voipio-Pulkki LM. Patient knowledge of atrial fibrillation: 3-month follow-up after an emergency room visit. J Adv Nurs. 2008 Jan;61(1):51-61. doi: 10.1111/j.1365-2648.2007.04465.x.</citation>
    <PMID>18173735</PMID>
  </reference>
  <reference>
    <citation>Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, Crandall BG, Osborn JS, Anderson JL, Horne BD, Muhlestein JB, Lappe DL, Moss H, Oliver J, Viau K, Bunch TJ. Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology. 2010;116(1):61-9. doi: 10.1159/000314936. Epub 2010 May 26.</citation>
    <PMID>20502012</PMID>
  </reference>
  <reference>
    <citation>Court H, Greenland K, Margrain TH. Measuring patient anxiety in primary care: Rasch analysis of the 6-item Spielberger State Anxiety Scale. Value Health. 2010 Sep-Oct;13(6):813-9. doi: 10.1111/j.1524-4733.2010.00758.x. Epub 2010 Jun 17.</citation>
    <PMID>20561315</PMID>
  </reference>
  <reference>
    <citation>Marjoram J, Strachan R, Allan A, Allan E. Screening for colorectal cancer: a general-practice-based study. Br J Gen Pract. 1996 May;46(406):283-86.</citation>
    <PMID>8762743</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Bryan Ping Yen YAN</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

